CD38 and plasma cell myeloma: Although the addition of CD38 mAbs to triplet regimens is associated with longer survival, this benefit is not consistent across all subgroups, particularly in NDMM patients with high-risk cytogenetics, a category which the 2016 International Myeloma Working Group (IMWG) consensus defined by identifying del(17p), t(4,14), and t(14,16) as primary lesions while also recognizing gain(1q) associated with del(1p) carrying poor risk (11).